This ASX 200 med-tech stock has no debt, pays dividends and is growing at 30% per year!

This stock is delivering very healthy growth.

| More on:
Three scientists wearing white coats and blue gloves dance together in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Ltd (ASX: PME) share price has performed exceptionally for shareholders over the last year, rising 99%. The S&P/ASX 200 Index (ASX: XJO) healthcare stock is also up 342% in the past five years, as shown in the chart below.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALL19 Jul 201919 Jul 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.com.au

Pro Medicus describes itself as a leading healthcare informatics company, providing a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. It offers a suite of RIS, PACS, AI and e-health solutions.

It was co-founded by Sam Hupert and Anthony Hall, who are now both billionaires.

The ASX 200 stock doesn't seem anywhere near finished growing.

Strong performance

According to reporting by the Australian Financial Review, Hupert told the newspaper that its success was partly due to the ability to scale the business without relying on debt. He was quoted by the newspaper saying:

At Pro Medicus, we are financially very conservative.

We make profits, pay dividends, have no debt but are still growing at 30 per cent-plus per year. This seems obvious, but you would be surprised how many companies, especially in tech, don't [get this].

Pro Medicus' FY24 first-half result was very promising, with total revenue rising 30.03% to $74.1 million.

That level of revenue growth is very good and justifies a higher valuation than most other businesses.

Its profit margins are incredibly high. The HY24 earnings before interest and tax (EBIT) margin was 66%, one of the highest on the ASX. This high-profit margin means a substantial amount of new revenue gets turned into new profit. HY24 EBIT rose by 31.5% to $48.9 million, while net profit after tax (NPAT) increased 33.3% to $36.3 million.

The company's balance sheet is debt-free and it had $131.5 million of cash and investments (up 8.3%) at December 2023.

The growing dividend sends a lot of the additional profit to shareholders each year. Owners of Pro Medicus shares saw a 38.5% rise in the interim dividend to 18 cents per share.

Ongoing impressive contract wins by the ASX 200 stock

The company keeps winning contracts – its latest announcement revealed five new contracts with a combined minimum value of $45 million. Those contracts ranged between five years to eight years in length. The most rewarding contract on a per-year basis was with Consulting Radiology, a private radiology group in Minnesota.

Pro Medicus revealed that the contracts bring the ASX 200 stock's minimum total contract value (TCV) for new sales this financial year to $245 million.

Pro Medicus share price valuation

According to the forecasts on Commsec, the Pro Medicus share price is valued at 131x FY25's estimated earnings and 102x FY26's estimated earnings. A premium price for a premium business.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »